# Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer

> **NCT00112528** · PHASE2 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 53 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** gemcitabine hydrochloride
- **DRUG:** oxaliplatin

## Key facts

- **NCT ID:** NCT00112528
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2006-08
- **Final completion:** 2010-11
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2016-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00112528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00112528, "Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00112528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*